62nd ASH Annual Meeting and Exposition: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III

Oral and Poster Abstracts
Poster

AML, apoptosis, Biological, therapy sequence, CML, Diseases, Non-Biological, CMML, Combinations, Therapies, cellular interactions, chemotherapy, MDS, Biological Processes, enzyme inhibitors, MPN, Technology and Procedures, gene editing, Clinically relevant, genetic profiling, Myeloid Malignancies, hematopoiesis, pharmacology, flow cytometry, TKI, integrative -omics, stem cells, NGS, microenvironment, pathogenesis, pathways, signal transduction

2777

Nicotinamide Phosphoribosyltransferase Inhibitors Induce Apoptosis of AML Stem Cells through Dysregulation of Lipid Metabolism

Amit Subedi, PhD¹, Qiang Liu, PhD, BSc², David Sharon, PhD³, Severine Cathelin, PhD¹^*, Gary D Bader⁴^*, Changjiang Xu⁵^*, Veronique Voisin, PhD⁶^*, Angelo D'Alessandro, PhD⁷^*, Eric R Lechman, Ph.D.¹^*, John E. Dick, PhD, FRS⁸, Mark D. Minden⁹, Jean C.Y. Wang, MD¹⁰ and Steven M Chan, MD, PhD¹¹

¹Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
²Princess Margaret, University Health Network, Toronto, ON, Canada
³University Health Network, Toronto, ON, Canada
⁴The Donnelly Centre, University of Toronto, Toronto, ON, Canada
⁵The Donnelly Centre, University of Toronto, Toronto, Canada
⁶University of Toronto, Toronto, ON, Canada
⁷Department of Biochemistry and Molecular Genetics, University of Colorado Denver - Anschutz Medical Campus, Aurora, CO
⁸Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, ON, Canada
⁹Leukemia Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
¹⁰Department of Medicine, Ontario Cancer Institute University Health Network, Toronto, ON, Canada
¹¹Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

2778

Venetoclax Inhibition of Pyrimidine Synthesis Guides Methods for Integration with Decitabine or 5-Azacytidine That Are Non-Myelosuppressive

Xiaorong Gu, PhD¹^*, Rita Tohme, PhD²^*, Mendel Goldfinger, MD³^*, Benjamin K. Tomlinson, MD^4,5, Nneha Sakre, PhD⁶^*, Shannon Hanmer⁶^*, Babal K. Jha, PhD¹^*, Jaroslaw P. Maciejewski, MD, PhD⁷, Amit Verma, MBBS³ and Yogenthiran Saunthararajah, MD¹

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
²Taussig Cancer Institute, Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
³Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
⁴Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
⁵Case Western Reserve University, Cleveland, OH
⁶Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
⁷Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2779

JAK/STAT Inhibition Targets TP53 altered Primary Human Acute Myeloid Leukemia Stem Cells

Marie Lue Antony, PhD^1,2^*, Klara Noble-Orcutt, BS, MS^1,2^*, Yoonku Lee, MS^1,2^*, Oluwateniayo Ogunsan²^*, Jeffrey Lee Jensen, MD, PhD²^*, Fiona He, MD^1,2 and Zohar Sachs, MD, PhD^1,2

¹Department of Medicine, Division of Hematology Oncology and Transplantation, University of Minnesota, Minneapolis, MN
²Masonic Cancer Center, University of Minnesota, Minneapolis, MN

2780

Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms

Simona Pagliuca, MD^1,2, Yihong Guan, PhD²^*, Anand D. Tiwari, PhD²^*, Dale Grabowski, BS²^*, Carmelo Gurnari, MD^2,3^*, Cassandra M Kerr, MS²^*, Sunisa Kongkiatkamon, MD^2,4^*, Metis Hasipek, PhD²^*, Laila Terkawi²^*, Misam Zawit, MBBS²^*, Hassan Awada, MD², Valeria Visconte, PhD², Yogenthiran Saunthararajah, MD², James G Phillips, PhD²^*, Jaroslaw P. Maciejewski, MD, PhD⁵ and Babal K. Jha, PhD²^*

¹Université de Paris, Cleveland, OH
²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
³Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
⁴Department of hematology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
⁵Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2781

Genetic Modulators of Niclosamide Sensitivity and Resistance in Acute Myeloid Leukemia

Anna Wojcicki, BS¹, Hee-Don Chae, PhD¹^*, Kyuho Han, PhD²^*, Minyoung Youn, PhD¹^*, Mark C Wilkes, PhD¹, Norman J. Lacayo, MD¹, Michael Bassik, PhD^2,3^* and Kathleen M. Sakamoto, MD, PhD¹

¹Department of Pediatrics, Stanford University School of Medicine, Stanford, CA
²Department of Genetics, Stanford University, Stanford, CA
³Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA

2782

Levels of Osteopontin (SPP1), Osteonectin (SPARC) and Biglycan (BGN) in Acute Myeloid Leukemia Bone Marrow Biopsies Post-Induction Therapy Define the Status of Osteogenic Niche and Show Inverse Correlation with Therapeutic Response

Diana O Treaba, MD^1,2^*, Dennis M Bonal³^*, Anna D Chorzalska, PhD⁴^*, Christoph Schorl, PhD⁵^*, Kelsey Hopkins¹^*, John L Reagan, MD⁶, Peter Rintels, MD⁷, Peter J Quesenberry, MD⁸ and Patrycja M Dubielecka, PhD⁴

¹Warren Alpert Medical School at Brown University, Providence, RI
²Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Providence, RI
³Signal Transduction Lab, Division of Hematology/Oncology at Rhode Island Hospital and Warren Alpert Medical School at Brown University, Providence, RI
⁴Signal Transduction Lab, Division of Hematology-Oncology, Rhode Island Hospital and Warren Alpert Medical School at Brown University, Providence, RI
⁵Genomics Core, Brown University, Providence, RI
⁶Division of Hematology/Oncology, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, RI
⁷Division of Hematology/Oncology, Rhode Island Hospital and Warren Alpert Medical School at Brown University, Providence, RI
⁸Division of Hematology and Oncology, Rhode Island Hospital, Providence, RI

2783

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

Bing Z Carter, PhD¹, Po Yee Mak¹^*, Vivian Ruvolo, MS¹^*, Wenjing Tao¹^*, Paul Hughes²^*, Xiaoyue Chen²^*, PK Morrow³^* and Michael Andreeff, MD, PhD¹

¹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Oncology Research, Amgen Inc., Thousand Oaks, CA
³Amgen Inc., Thousand Oaks, CA

2784

Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach: Mycare-021-01

Scott Howard, MD¹, Prashant Ramachandran Nair, B.Tech.²^*, Himanshu Grover, M.S.²^*, Anuj Tyagi, M.Sc.²^*, Pallavi Kumari, M.Sc.²^*, Samiksha Avinash Prasad, M.Sc.²^*, Upasana Mitra, M.Sc.²^*, Deepak Anil Lala, B.Tech.²^*, Humera Azam, M.Sc.²^*, Neha Gupta, M.Sc.²^*, Subrat Mohapatra, M.Sc.²^*, Poornachandra G, B.Tech.²^*, Nirjhar Mundkur³^*, Michele Dundas Macpherson, B.A.Sc.⁴^* and Shweta Kapoor, M.Sc.²^*

¹University of Tennessee Health Science Center, Memphis, TN
²Cellworks Research India Private Limited, Bangalore, India
³Cellworks Group Inc., San Jose, CA
⁴Cellworks Group Inc., South San Francisco, CA

2785

BCL2A1: A Novel Target in Refractory Acute Myeloid Leukemia with FLT3-ITD/D835 Dual Mutations

Kotoko Yamatani, MD^1,2^*, Tomohiko Ai, MD, PhD²^*, Kaori Saito²^*, Haeun Yang²^*, Vivian Ruvolo, MS³^*, Po Yee Mak³^*, Sonoko Kinjo, PhD⁴^*, Kazuho Ikeo, PhD⁴^*, Hironori Harada, MD, PhD⁵, Kazuhiro Katayama, PhD⁶^*, Takashi Miida, MD, PhD²^*, Marina Konopleva, MD, PhD⁷, Weiguo Zhang, MD, PhD⁸, Bing Z Carter, PhD⁹, Yoshihide Hayashizaki, MD, PhD¹⁰^*, Michael Andreeff, MD, PhD³ and Yoko Tabe, MD, PhD^2,11

¹Research Fellow of the Japan Society for the Promotion of Science, Tokyo, Japan
²Department of Clinical Laboratory Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan
³Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Centers for Information Biology, National Institute of Genetics, Shizuoka, Japan
⁵Department of Hematology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
⁶Laboratory of Molecular Targeted Therapeutics, School of Pharmacy, Nihon University, Chiba, Japan
⁷Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX
⁸Section of Molecular Hematology and Therapy, Department of Leukemia, U.T.M.D. Anderson Cancer Center, Houston, TX
⁹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
¹⁰Preventive Medicine & Diagnosis Innovation Program, RIKEN Center for Life Science Technoligies, Kanagawa, Japan
¹¹Section of Molecular Hematology and Therapy, Department of Leukemia, MD Anderson Cancer Center, Houston, TX

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH